Literature DB >> 17883951

Structure-efficacy relationships of immunostimulatory activity of CpG-containing oligodeoxynucleotides on mouse spleen cells.

Hai-Yan Du1, Shao-You Xia, Hai-Feng Song, Na Li, Ming-Mei Shang, Jia Zou, Qing-Qing Wang, Lun Ou, Xiao Sun, Ai-Guo Ji, Zhong-Ming Tang.   

Abstract

AIM: To study the relationship between primary structures of oligodeoxynucleotides (ODN) containing unmethylated deoxycytidyldeoxyguanosine (CpG) dinucleotide motifs and their immunostimulatory activities in mouse spleen cells.
METHODS: A series of CpG ODN with different primary structures were synthesized. Their capabilities to stimulate mouse spleen cell proliferation were determined by [3H]thymidine incorporation assay. Cytokine (interleukin [IL]-6, IL-12, and IFN-alpha) secretion spectra induced by CpG ODN were assessed by ELISA. The ability of CpG ODN to activate natural killer cells was evaluated by standard 4 h (51)Cr-release assay. Flow cytometry was utilized to examine the expressions of various lymphocyte surface molecules on diverse immunocytes. An effective CpG ODN for murine, ODN1826, was set as the template of modification and the positive control.
RESULTS: The immunostimulatory activities of CpG ODN with different sequences and compositions varied markedly, both in character and in extent. It was useless for improving the immunostimulatory activity of ODN1826 by simply increasing the functional hexameric CpG motif number, modifying the site of CpG motifs, or changing the distance between multi-CpG motifs. However, an addition of a self-complementary palindrome structure at the 3'-end, but not the 5'-end of CpG ODN, aroused marked improvement in its activity. Several designed ODN had superior comprehensive immunostimulatory properties compared to ODN1826.
CONCLUSION: The immunostimulatory activity of a CpG ODN was relevant to its primary structure. It was useless for promoting immunostimulatory activity to simply change CpG motif number, space, or distance. The 3'-end palindrome structure of CpG ODN is associated with enhanced immunostimulatory activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17883951      PMCID: PMC7091584          DOI: 10.1111/j.1745-7254.2007.00628.x

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  30 in total

1.  Accessible 5'-end of CpG-containing phosphorothioate oligodeoxynucleotides is essential for immunostimulatory activity.

Authors:  D Yu; Q Zhao; E R Kandimalla; S Agrawal
Journal:  Bioorg Med Chem Lett       Date:  2000-12-04       Impact factor: 2.823

2.  Effects of a hexameric deoxyriboguanosine run conjugation into CpG oligodeoxynucleotides on their immunostimulatory potentials.

Authors:  S W Lee; M K Song; K H Baek; Y Park; J K Kim; C H Lee; H K Cheong; C Cheong; Y C Sung
Journal:  J Immunol       Date:  2000-10-01       Impact factor: 5.422

3.  Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells.

Authors:  A Krug; S Rothenfusser; V Hornung; B Jahrsdörfer; S Blackwell; Z K Ballas; S Endres; A M Krieg; G Hartmann
Journal:  Eur J Immunol       Date:  2001-07       Impact factor: 5.532

4.  'Immunomers'--novel 3'-3'-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents.

Authors:  Dong Yu; Ekambar R Kandimalla; Lakshmi Bhagat; Jin-Yan Tang; Yanping Cong; Jimmy Tang; Sudhir Agrawal
Journal:  Nucleic Acids Res       Date:  2002-10-15       Impact factor: 16.971

5.  Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction.

Authors:  Kenya Honda; Yusuke Ohba; Hideyuki Yanai; Hideo Negishi; Tatsuaki Mizutani; Akinori Takaoka; Choji Taya; Tadatsugu Taniguchi
Journal:  Nature       Date:  2005-04-06       Impact factor: 49.962

6.  Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds.

Authors:  D E Macfarlane; L Manzel
Journal:  J Immunol       Date:  1998-02-01       Impact factor: 5.422

7.  CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved.

Authors:  R Rankin; R Pontarollo; X Ioannou; A M Krieg; R Hecker; L A Babiuk; S van Drunen Littel-van den Hurk
Journal:  Antisense Nucleic Acid Drug Dev       Date:  2001-10

8.  Phosphodiester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo.

Authors:  Alexander H Dalpke; Stefan Zimmermann; Inka Albrecht; Klaus Heeg
Journal:  Immunology       Date:  2002-05       Impact factor: 7.397

9.  Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides.

Authors:  Q Zhao; S Matson; C J Herrera; E Fisher; H Yu; A M Krieg
Journal:  Antisense Res Dev       Date:  1993

10.  Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties.

Authors:  Dong Yu; Fu-Gang Zhu; Lakshmi Bhagat; Hui Wang; Ekambar R Kandimalla; Ruiwen Zhang; Sudhir Agrawal
Journal:  Biochem Biophys Res Commun       Date:  2002-09-13       Impact factor: 3.575

View more
  2 in total

1.  Immunostimulatory and anti-neoplasm effects of a novel palindrome CpG oligodeoxynucleotide in mice.

Authors:  Hai-yan Du; Li-hou Dong; Bi-jun Zhao; Jie Fu; Qing-qing Wang; Fang Chen; Lun Ou; Na Li; Xiao Sun; Zhong-ming Tang; Hai-feng Song
Journal:  Acta Pharmacol Sin       Date:  2012-06-25       Impact factor: 6.150

2.  A Novel C Type CpG Oligodeoxynucleotide Exhibits Immunostimulatory Activity In Vitro and Enhances Antitumor Effect In Vivo.

Authors:  Tete Li; Jing Wu; Shan Zhu; Guoxia Zang; Shuang Li; Xinping Lv; Wenjun Yue; Yuan Qiao; Jiuwei Cui; Yan Shao; Jun Zhang; Yong-Jun Liu; Jingtao Chen
Journal:  Front Pharmacol       Date:  2020-02-06       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.